SciClone, Sigma-Tau Updates On Zadaxin Trial
According to investigators, Zadaxin treatment given with the H1N1 vaccine led to an (p value=0.04) increase in the percentage of subjects who seroconverted, also when evaluated 42 days
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).